Tizona Therapeutics Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
24
- Latest Deal Type
-
2ndary - Private
- Investors
-
8
Tizona Therapeutics General Information
Description
Operator of a biopharmaceutical company intended to improve outcomes for people with cancer by translating novel scientific insights into immunotherapies. The company offers innovative immunotherapy programs and collaborative research efforts, enabling cancer patients and healthcare providers to access transformative treatment options.
Contact Information
Website
www.tizonatx.comCorporate Office
- 611 Gateway Boulevard
- Suite 221
- South San Francisco, CA 94080
- United States
Corporate Office
- 611 Gateway Boulevard
- Suite 221
- South San Francisco, CA 94080
- United States
Tizona Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Secondary Transaction - Private | 01-Dec-2022 | Completed | Clinical Trials - Phase 1 | |||
| 8. Later Stage VC | 21-Jul-2020 | Completed | Clinical Trials - Phase 1 | |||
| 7. Later Stage VC (Series B3) | 10-Jan-2019 | Completed | Clinical Trials - Phase 1 | |||
| 6. Later Stage VC | 03-Jan-2019 | Completed | Clinical Trials - Phase 1 | |||
| 5. Debt - General | 06-Sep-2018 | Completed | Pre-Clinical Trials | |||
| 4. Early Stage VC (Series B2) | 04-Aug-2017 | Completed | Pre-Clinical Trials | |||
| 3. Early Stage VC (Series B) | 23-Feb-2016 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series A) | 17-Sep-2015 | $27M | $27M | Completed | Startup | |
| 1. Accelerator/Incubator | 31-Jul-2015 | Completed | Startup |
Tizona Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B3 | ||||||||
| Series B2 | ||||||||
| Series B | 13,333,332 | $0.000100 | $0.01 | $1.5 | $1.5 | 1x | $1.5 | 13.33% |
| Series A | 27,217,500 | $0.000100 | $0.08 | $1 | $1 | 1x | $1 | 27.22% |
Tizona Therapeutics Comparisons
Industry
Financing
Details
Tizona Therapeutics Competitors (44)
One of Tizona Therapeutics’s 44 competitors is Perthera, a Venture Capital-Backed company based in McLean, VA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Perthera | Venture Capital-Backed | McLean, VA | ||||
| Secura Bio | Private Equity-Backed | Las Vegas, NV | ||||
| PNP Therapeutics | Formerly VC-backed | Birmingham, AL | ||||
| Valerio Therapeutics | Formerly VC-backed | Paris, France | ||||
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA |
Tizona Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Tizona Therapeutics Patents
Tizona Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2025273195-A1 | Combination therapy involving anti-hla-g antibodies and anti- egfr antibodies or anti-pd-1 antibodies | Pending | 22-May-2024 | ||
| WO-2025245256-A1 | Combination therapy involving anti-hla-g antibodies and anti- egfr antibodies or anti-pd-1 antibodies | Pending | 22-May-2024 | ||
| WO-2025213047-A1 | Anti-il-18bp antibodies, compositions comprising anti-il-18bp antibodies and methods of using anti-il-18bp antibodies | Pending | 05-Apr-2024 | ||
| WO-2025165879-A1 | Methods of using anti-hla-g antibodies | Pending | 29-Jan-2024 | ||
| WO-2025054320-A1 | Anti-ackr4 antibodies, compositions and uses thereof | Inactive | 05-Sep-2023 | C07K16/2866 |
Tizona Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Tizona Therapeutics Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Gilead | Corporation | Minority | ||
| AbbVie | Corporation | Minority | ||
| InterWest Partners | Venture Capital | Minority | ||
| Abingworth | Venture Capital | Minority | ||
| Canaan Partners | Venture Capital | Minority |
Tizona Therapeutics FAQs
-
When was Tizona Therapeutics founded?
Tizona Therapeutics was founded in 2014.
-
Where is Tizona Therapeutics headquartered?
Tizona Therapeutics is headquartered in South San Francisco, CA.
-
What is the size of Tizona Therapeutics?
Tizona Therapeutics has 24 total employees.
-
What industry is Tizona Therapeutics in?
Tizona Therapeutics’s primary industry is Drug Discovery.
-
Is Tizona Therapeutics a private or public company?
Tizona Therapeutics is a Private company.
-
What is Tizona Therapeutics’s current revenue?
The current revenue for Tizona Therapeutics is .
-
How much funding has Tizona Therapeutics raised over time?
Tizona Therapeutics has raised $520M.
-
Who are Tizona Therapeutics’s investors?
Gilead, AbbVie, InterWest Partners, Abingworth, and Canaan Partners are 5 of 8 investors who have invested in Tizona Therapeutics.
-
Who are Tizona Therapeutics’s competitors?
Perthera, Secura Bio, PNP Therapeutics, Valerio Therapeutics, and Sorrento Therapeutics are some of the 44 competitors of Tizona Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
